Combination of estramustine, paclitaxel, and tegafur-uracil (ETU) in patients with metastatic hormone-refractory prostate cancer (mHRPC): Efficacy and safety results of a multicenter phase II study

被引：0
|
作者：
Fitoussi, O.
Guichard, F.
Hirt, S.
Dohollou, N.
Bureau, C.
Auduhy, F.
Guichard, P.
机构：
[1] Polyclin Bordeaux N Aquitaine, Bordeaux, France
[2] Merck Lipha Sante, Lyon, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.16027
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
16027
引用
收藏
页数：1
相关论文
共 50 条
  • [1] EFFICACY AND SAFETY OF A COMBINATION OF ESTRAMUSTINE, PACLITAXEL, AND UFT (TEGAFUR-URACIL) (ETU) IN PATIENTS WITH METASTATIC HORMONE-REFRACTORY PROSTATE CANCER (MHRPC): RESULTS OF A MULTICENTER PHASE II STUDY
    Fitoussi, O.
    Guichard, F.
    Hirt, S.
    Dohollou, N.
    Bureau, C.
    Audhuy, F.
    Guichard, P.
    ANNALS OF ONCOLOGY, 2008, 19 : 199 - 199
  • [2] Paclitaxel, tegafur-uracil and estramustine in patients with metastatic hormone-refractory prostate cancer: Preliminary results of a multicenter phase ii study
    Fitoussi, Olivier
    Guichard, Pierre
    Hirt, Sandrine
    Savary, Jacqueline
    Dohollou, Nadine
    Dahan, Olivier
    Guichard, Francois
    ANNALS OF ONCOLOGY, 2006, 17 : 149 - 149
  • [3] Oral combination of cyclophosphamide, uracil plus tegafur and estramustine for hormone-refractory prostate cancer
    Nishimura, K
    Nonomura, N
    Ono, Y
    Nozawa, M
    Fukui, T
    Harada, Y
    Imazu, T
    Takaha, N
    Sugao, H
    Miki, T
    Okuyama, A
    ONCOLOGY, 2001, 60 (01) : 49 - 54
  • [4] A phase II study of weekly paclitaxel/estramustine/carboplatin in hormone-refractory prostate cancer
    Berry, William
    Friedland, David
    Fleagle, John
    Jackson, Dori
    Ilegbodu, Des
    Boehm, Kristi A.
    Asmar, Lina
    CLINICAL GENITOURINARY CANCER, 2006, 5 (02) : 131 - 137
  • [5] Sunitinib in combination with docetaxel and prednisone in patients with metastatic hormone-refractory prostate cancer (mHRPC) - preliminary results
    George, D. J.
    Liu, G.
    Wilding, G.
    Hutson, T. E.
    Chen, I.
    Maneval, E. Chow
    Logothetis, C. J.
    Zurita, A. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [6] EFFICACY AND SAFETY OF THE ASSOCIATION OF PACLITAXEL AND ESTRAMUSTINE WITH ZOLENDRONIC ACID, IN METASTATIC HORMONE-REFRACTORY PROSTATE CARCINOMA
    Chiesa, M. Dalla
    Negri, F.
    Bergonzi, C.
    Musolino, A.
    Perrone, A.
    Potenzoni, D.
    Cantoni, C.
    Di Giovanni, M.
    Donati, G. V.
    Passalacqua, R.
    ANNALS OF ONCOLOGY, 2004, 15 : 97 - 97
  • [7] PACLITAXEL PLUS ESTRAMUSTINE IN METASTATIC HORMONE-REFRACTORY PROSTATE-CANCER
    HUDES, GR
    NATHAN, FE
    KHATER, C
    GREENBERG, R
    GOMELLA, L
    STERN, C
    MCALEER, C
    SEMINARS IN ONCOLOGY, 1995, 22 (05) : 41 - 45
  • [8] SUNITINIB IN COMBINATION WITH DOCETAXEL AND PREDNISONE IN PATIENTS WITH METASTATIC HORMONE-REFRACTORY PROSTATE CANCER (MHRPC)
    Zurita, A. J.
    Logothetis, C. J.
    Liu, G.
    Wilding, G.
    Hutson, T. E.
    Chen, I.
    Chow-Maneval, E.
    George, D. J.
    ANNALS OF ONCOLOGY, 2008, 19 : 198 - 198
  • [9] Sunitinib in combination with docetaxel and prednisone in patients (pts) with metastatic hormone-refractory prostate cancer (mHRPC)
    Zurita, A. J.
    Liu, G.
    Hutson, T.
    Kozloff, M.
    Shore, N.
    Wilding, G.
    Logothetis, C. J.
    Chen, I.
    Maneval, E. Chow
    George, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [10] Weekly paclitaxel plus estramustine combination therapy in hormone-refractory prostate cancer: A pilot study
    Kuruma, H
    Fujita, T
    Shitara, T
    Egawa, S
    Yokoyama, E
    Baba, S
    INTERNATIONAL JOURNAL OF UROLOGY, 2003, 10 (09) : 470 - 475
12345